Three years after launching a forward-thinking diabetes prevention programme, NHS England yesterday hailed early signs of a very significant impact on those at-risk people taking part.
New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
John Grumitt, vice president of Diabetes UK and chief executive of Changing Health, says digital health innovators can work with big pharma to address medical needs.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.